NASDAQ:CBAY - CymaBay Therapeutics Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$14.00 +0.03 (+0.21 %)
(As of 06/19/2018 02:19 PM ET)
Previous Close$14.29
Today's Range$13.75 - $14.29
52-Week Range$4.82 - $15.59
Volume48,074 shs
Average Volume756,121 shs
Market Capitalization$811.60 million
P/E Ratio-17.76
Dividend YieldN/A
Beta2.09
CymaBay Therapeutics logoCymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar, a selective agonist of peroxisome proliferator-activated receptor delta, which has completed Phase II clinical study for the treatment of primary biliary cholangitis, as well as patients with nonalcoholic steatohepatitis. The company also develops arhalofenate, which has completed five Phase II clinical trials for the treatment of patients with gout; and MBX-2982, an oral G-protein coupled receptor agonist that has completed one Phase II clinical trial for therapeutic indications. It has licensing agreement with Kowa Pharmaceuticals America, Inc. for the development and commercialization of arhalofenate in the United States; and Janssen Pharmaceuticals, Inc. to develop and discover undisclosed metabolic disease target agonists for the treatment of type II diabetes and other disorders, as well as a license and development agreement with DiaTex, Inc. to develop and commercialize therapeutic products comrprising halofenate and its enantiomers, derivatives, and analogs for the treatment of diseases. The company was formerly known as Metabolex, Inc. CymaBay Therapeutics, Inc. was incorporated in 1988 and is headquartered in Newark, California.

Receive CBAY News and Ratings via Email

Sign-up to receive the latest news and ratings for CBAY and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:CBAY
CUSIPN/A
Phone510-293-8800

Debt

Debt-to-Equity Ratio0.01
Current Ratio12.91
Quick Ratio12.91

Price-To-Earnings

Trailing P/E Ratio-17.76
Forward P/E Ratio-11.86
P/E GrowthN/A

Sales & Book Value

Annual Sales$10 million
Price / Sales82.28
Cash FlowN/A
Price / CashN/A
Book Value$1.53 per share
Price / Book9.15

Profitability

EPS (Most Recent Fiscal Year)($0.79)
Net Income$-27,550,000.00
Net MarginsN/A
Return on Equity-40.66%
Return on Assets-34.13%

Miscellaneous

Employees26
Outstanding Shares58,770,000

CymaBay Therapeutics (NASDAQ:CBAY) Frequently Asked Questions

What is CymaBay Therapeutics' stock symbol?

CymaBay Therapeutics trades on the NASDAQ under the ticker symbol "CBAY."

How were CymaBay Therapeutics' earnings last quarter?

CymaBay Therapeutics Inc (NASDAQ:CBAY) posted its quarterly earnings results on Wednesday, May, 9th. The biopharmaceutical company reported ($0.32) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.14) by $0.18. View CymaBay Therapeutics' Earnings History.

When is CymaBay Therapeutics' next earnings date?

CymaBay Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, August, 9th 2018. View Earnings Estimates for CymaBay Therapeutics.

What price target have analysts set for CBAY?

11 brokers have issued 1-year price objectives for CymaBay Therapeutics' stock. Their predictions range from $15.00 to $27.00. On average, they anticipate CymaBay Therapeutics' stock price to reach $19.00 in the next twelve months. View Analyst Ratings for CymaBay Therapeutics.

What are Wall Street analysts saying about CymaBay Therapeutics stock?

Here are some recent quotes from research analysts about CymaBay Therapeutics stock:
  • 1. According to Zacks Investment Research, "CymaBay Therapeutics Inc. is a biopharmaceutical company. It is focused on the development and commercialization of proprietary new medicines for important human diseases. The Company's lead product candidate, arhalofenate, is being developed for the treatment of gout. CymaBay Therapeutics Inc. is based in Newark, California. " (6/12/2018)
  • 2. HC Wainwright analysts commented, "EASL; Phase 3 Initiation in 2H18 on Track; Affirm Buy Stock Data 03/27/2018 Price $12.00 Exchange NASDAQ Price Target $18.00 52-Week High $15.59 52-Week Low $3.16 Enterprise Value (M) $611.7 Market Cap (M) $702 Public Market Float (M) 19.5 Shares Outstanding (M) 58.5 3 Month Avg Volume 980,454 Short Interest (M) 2.59 Balance Sheet Metrics Cash (M) $97.2 Total Debt (M) $6.9 Total Cash/Share $1.66 Book Value/Share $2.16 Cash (M): Amount shown is as of December 31 and does not include the $135.5M net proceeds from the recent equity raise.. EPS Diluted Full Year – Dec 2016A 2017A 2018E 1Q (0.29) (0.20) (0.21) 2Q (0.30) (0.31) (0.22) 3Q (0.25) (0.21) (0.25) 4Q (0.30) (0.11) (0.27) FY (1.14) (0.79) (0.95) Revenue ($M) Full Year – Dec 2016A 2017A 2018E 1Q 0.0 4.8 0.0 2Q 0.0 0.0 0.0 3Q 0.0 0.0 0.0 4Q 0.0 5.2 0.0 FY 0.0 10.0 5.0 20 15 10 5 0 MAR- 17 J UL- 17 NOV- 17 MAR- 18 12 10 8 6 4 2 0 Vol." (3/28/2018)
  • 3. Cantor Fitzgerald analysts commented, "Clarity on Phase 3 PBC trial design should come before end of 2Q18. Management noted that discussions with U.S. and European regulators are ongoing and expressed pleasure with the level of engagement. Once the details have been finalized, the company expects to share them with the Street. High level, the company anticipates conducting a single pivotal study involving a treatment period of 12 months." (3/16/2018)

Who are some of CymaBay Therapeutics' key competitors?

Who are CymaBay Therapeutics' key executives?

CymaBay Therapeutics' management team includes the folowing people:
  • Dr. Charles A. McWherter, Sr. VP & Chief Scientific Officer (Age 63)
  • Dr. Pol F. Boudes, Chief Medical Officer (Age 61)
  • Mr. Sujal A. Shah, Pres, CEO & Director (Age 45)
  • Mr. Daniel Menold, VP of Fin. (Age 48)
  • Mr. Paul T. Quinlan, Gen. Counsel & Sec. (Age 55)

Has CymaBay Therapeutics been receiving favorable news coverage?

Headlines about CBAY stock have been trending somewhat positive on Tuesday, Accern reports. Accern rates the sentiment of press coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. CymaBay Therapeutics earned a news impact score of 0.09 on Accern's scale. They also gave news headlines about the biopharmaceutical company an impact score of 46.07 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the next few days.

Who are CymaBay Therapeutics' major shareholders?

CymaBay Therapeutics' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Redmile Group LLC (5.03%), Foresite Capital Management IV LLC (3.59%), Franklin Resources Inc. (3.06%), Foresite Capital Management III LLC (2.66%), BlackRock Inc. (1.99%) and Millennium Management LLC (1.97%). Company insiders that own CymaBay Therapeutics stock include Carl Goldfischer, Charles Mcwherter, Kurt Von Emster, Robert James Wills and Sujal Shah. View Institutional Ownership Trends for CymaBay Therapeutics.

Which institutional investors are selling CymaBay Therapeutics stock?

CBAY stock was sold by a variety of institutional investors in the last quarter, including Abingworth LLP, Farallon Capital Management LLC, Foresite Capital Management IV LLC, Barclays PLC, DAFNA Capital Management LLC, Baird Financial Group Inc., Alpine Global Management LLC and EAM Global Investors LLC. Company insiders that have sold CymaBay Therapeutics company stock in the last year include Carl Goldfischer and Kurt Von Emster. View Insider Buying and Selling for CymaBay Therapeutics.

Which institutional investors are buying CymaBay Therapeutics stock?

CBAY stock was bought by a variety of institutional investors in the last quarter, including Millennium Management LLC, Foresite Capital Management III LLC, Redmile Group LLC, BlackRock Inc., Artal Group S.A., Citadel Advisors LLC, Franklin Resources Inc. and Nexthera Capital LP. Company insiders that have bought CymaBay Therapeutics stock in the last two years include Charles Mcwherter, Robert James Wills and Sujal Shah. View Insider Buying and Selling for CymaBay Therapeutics.

How do I buy shares of CymaBay Therapeutics?

Shares of CBAY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is CymaBay Therapeutics' stock price today?

One share of CBAY stock can currently be purchased for approximately $14.00.

How big of a company is CymaBay Therapeutics?

CymaBay Therapeutics has a market capitalization of $811.60 million and generates $10 million in revenue each year. The biopharmaceutical company earns $-27,550,000.00 in net income (profit) each year or ($0.79) on an earnings per share basis. CymaBay Therapeutics employs 26 workers across the globe.

How can I contact CymaBay Therapeutics?

CymaBay Therapeutics' mailing address is 7999 GATEWAY BLVD SUITE 130, NEWARK CA, 94560. The biopharmaceutical company can be reached via phone at 510-293-8800 or via email at [email protected]


MarketBeat Community Rating for CymaBay Therapeutics (CBAY)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  250 (Vote Outperform)
Underperform Votes:  165 (Vote Underperform)
Total Votes:  415
MarketBeat's community ratings are surveys of what our community members think about CymaBay Therapeutics and other stocks. Vote "Outperform" if you believe CBAY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CBAY will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/19/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.